Related Experiment Video

Updated: Jun 27, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K

Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review

Deekshitha Alla1, Dhruv Jayeshkumar Shah2, Muneesh Seepana3

  • 1Andhra Medical College, Visakhapatnam, Andhra Pradesh, India.

Global Pediatric Health
|April 30, 2024
PubMed

Insights

Proton pump inhibitors (PPIs) are effective for pediatric acid-related disorders but carry risks. A review of over 762,000 children found adverse effects in 6.98%, necessitating judicious use and patient education.

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacology
  • Clinical Research

Background:

  • Proton pump inhibitors (PPIs) are frequently prescribed for pediatric acid-related conditions.
  • Established efficacy for peptic diseases, GERD, and H. pylori in children over one year old.
  • Prolonged PPI use is associated with increased risks of adverse events.

Purpose of the Study:

  • To analyze the adverse effects associated with PPI use in pediatric patients.
  • To identify the most common adverse events reported in children receiving PPIs.

Main Methods:

  • Systematic review of 30 articles.
  • Inclusion of data from 762,005 pediatric patients.

Main Results:

  • Adverse effects were reported in 6.98% of the pediatric population studied.
  • The five most frequent adverse effects included respiratory tract complications, gastrointestinal complications, urinary tract infections, asthma, and ENT infections.

Conclusions:

  • Proton pump inhibitors (PPIs) should be prescribed judiciously in pediatric patients.
  • Physicians must prioritize comprehensive patient education regarding PPI risks and benefits.

Keywords:
GI infectionsadverse effectspediatric populationproton pump inhibitorssecondary infections

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

19.4K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.8K

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
387
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
432
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
393
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
418
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
165